Healthcare Resource Utilization for Anemia Management: Current Practice with Erythropoiesis-Stimulating Agents and the Impact of Converting to Once-Monthly CERA

Background and Methods: A prospective, observational study in 12 German and UK dialysis centers which quantified personnel time for anemia treatment using erythropoiesis-stimulating agents (ESAs). Tasks directly observable were measured through the time-and-motion method; time for non-observable tasks was estimated by healthcare staff. Using activity-based costing methods, time was converted into monetary units. Modeling was used to estimate potential time and cost savings using once-monthly C. E. R. A., a continuous erythropoietin receptor activator. Results: For current ESAs in Germany and the UK, respectively: mean observed time was 1.67 and 2.67 min/patient/administration, corresponding to 31 and 42 days/year/center/100 patients; mean total time/center/100patients/year was estimated at 79 and 95 days, equivalent to EUR 17,031 and GBP 18,739. Assuming 100% once-monthly C. E. R. A. uptake, the observed time/patient/year may decrease by 79 and 84% in Germany and the UK, respectively, compared with traditional ESAs. Conclusion: Conversion to once-monthly C. E. R. A. may offer the potential to reduce time spent on ESA administration in hemodialysis centers. Copyright (C) 2008 S. Karger AG, Basel